08:38 AM EDT, 05/15/2025 (MT Newswires) -- Amneal Pharmaceuticals ( AMRX ) said Thursday that the US Food and Drug Administration has approved Brekiya injection to treat migraines with or without aura and the acute treatment of cluster headaches in adults.

Brekiya is the company's brand name for dihydroergotamine.

Shares of Amneal Pharmaceuticals ( AMRX ) were up more than 6% in recent premarket acitivty.

Price: 7.80, Change: +0.45, Percent Change: +6.12